EGFR and breast carcinoma: Surprisingly, although this mAb displays insufficient effect against EGFR-overexpressing breast cancer, it has yielded positive clinical results against head and neck cancers overexpressing the EGFR and has demonstrated activity in colon cancer regardless of tumor EGFR expression [30-32].